A First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Subjects
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs BGB-23339 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man
- Sponsors BeiGene
- 01 Feb 2023 Status changed from recruiting to completed.
- 22 Dec 2022 Planned End Date changed from 1 Oct 2022 to 1 Jun 2023.
- 22 Dec 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Mar 2023.